Lymphoma in Children

It is very rare for a child to be diagnosed with cancer. To be diagnosed with a subtype of lymphoma is extraordinarily rare.

Lymphoma in Children: The Statistics

The National Cancer Institute offers some fast facts for pediatric NHLs:

  • There are approximately 800 cases of lymphoma diagnosed among children under the age of 20 in the US annually.
  • This represents about 7 percent of all childhood cancers.
  • It also qualifies it for the third most common cancer in children.
  • Very rarely are children under 3 years old found to have an NHL; typically NHLs are diagnosed in the second decade of a child's life.
  • NHLs are slightly more common in boys than girls, and more common in white people than black people.

Pediatric Non-Hodgkin's Lymphomas

Generally, three subtypes of NHLs are diagnosed in children:

  • Diffuse, Small Noncleaved-Cell/Burkitt's Lymphoma: Aggressive, mature B-cell diseases, they are the most commonly diagnosed pediatric non-Hodgkin's lymphoma, accounting for about 50 percent.
  • Lymphoblastic Lymphoma: This disease accounts for about 30 percent of pediatric NHLs and tends to be precursor T-cell lymphoma more often than precursor B-cell lymphoma. Lymphoblastic lymphoma and childhood acute lymphoblastic leukemia are regarded as being different manifestations of the same disease. It is almost always found in the central nervous system and the bone marrow.
  • Anaplastic Large Cell Lymphoma: These are mature T-cell or null-cell lymphomas representing a group of heterogeneous diseases.

Generally speaking, the cure rate (meaning the relative five-year survival rate) among children with an NHL is around 80 percent, but that figure can be influenced by a variety of prognostic factors.

Pediatric Hodgkin's Lymphoma

Pediatric Hodgkin's lymphoma accounts for 6 percent of childhood cancers. Kids between the ages of 15-19 are the highest risk age group for childhood Hodgkin's, and the incidence is slightly higher in girls at that age than it is in boys.

Currently it has a cure rate of 90 to 95 percent.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap